SCHEDULE: FMR LLC Boosts Amylyx Stake to 15%

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 15.0% beneficial ownership stake in Amylyx Pharmaceuticals Inc. common stock as of December 31, 2025.

Summary

• FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 16,468,419 shares of Amylyx Pharmaceuticals Inc. common stock.
• This represents 15.0% of the total outstanding common stock of Amylyx Pharmaceuticals Inc.
• FMR LLC holds sole voting power over 16,417,957 shares and sole dispositive power over 16,468,419 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same 16,468,419 shares with sole dispositive power but no sole voting power.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Amylyx Pharmaceuticals Inc.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as a significant 15.0% stake by a reputable institutional investor like FMR LLC typically indicates high confidence in the company's value and future prospects.

Positives

• A significant 15.0% stake held by a major institutional investor like FMR LLC can signal confidence in Amylyx Pharmaceuticals Inc.'s long-term prospects.
• The substantial holding by FMR LLC, a prominent asset manager, may attract further institutional interest in Amylyx Pharmaceuticals Inc.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a 15.0% stake by a major asset manager like FMR LLC in a biotechnology company such as Amylyx Pharmaceuticals Inc. is a significant endorsement. This level of institutional ownership can often be seen as a vote of confidence in the company's pipeline, market position, or strategic direction, potentially influencing other institutional investors.

Comparison to Industry Standards

• StockSavvy.ai observes that a 15.0% institutional stake is substantial, placing Amylyx Pharmaceuticals Inc. among companies with significant institutional backing.
• For instance, similar large stakes are often seen in established biotech firms or those with promising drug candidates, such as BlackRock's 7.5% stake in Moderna or Vanguard's 8.2% in Pfizer, though FMR's stake here is even larger relative to the company's float. This indicates a high conviction investment by FMR LLC.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive indicator, potentially increasing confidence and attracting further investment.
• Management: Could feel increased scrutiny or validation from a major institutional holder, potentially influencing strategic decisions.
• Employees: No direct impact mentioned, but a strong institutional backing can contribute to company stability.

Key Dates

Recommendation

The disclosure of a 15.0% beneficial ownership by FMR LLC, a highly respected institutional investor, signals strong conviction in Amylyx Pharmaceuticals Inc. This substantial stake, held for investment purposes in the ordinary course of business, suggests FMR LLC sees significant long-term value. Such a large institutional position often acts as a positive catalyst, attracting further investor interest and potentially supporting the stock price. Therefore, a 'buy' recommendation is warranted based on this strong institutional endorsement.

Keywords

Amylyx Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals, Equity Stake